Analysis of blood gas beyond bicarbonate in outpatients with stage 3–5 chronic kidney disease
Author:
Bozaci Ilter1ORCID, Doğan Ali Nazmi Can2, Aktar Merve2, Mahşer Alev2, Yıldırım Gizem2, Serel Ali2, Tatar Erhan1
Affiliation:
1. Department of Nephrology , Bozyaka Education and Research Hospital, University of Healthy Sciences , Izmir , Turkey 2. Department of Internal Medicine , Bozyaka Education and Research Hospital, University of Healthy Sciences , Izmir , Turkey
Abstract
Abstract
Objectives
Metabolic acidosis is a common disorder seen in course of chronic kidney disease (CKD). In this study, we aimed to investigate the association of Base excess (BE), Anion gap (AG) and Delta Ratio with progression of CKD, renal replacement therapy (RRT) requirement and mortality in patients with stage 3–5 CKD.
Methods
A total of 212 patients with stage 3–5 CKD were included in this study. Patients were divided into two groups according to the baseline BE level. Patients were also grouped according to the delta ratio such as non- AG, High AG and mixed type.
Results
Mean BE level was significantly lower (−4.7 ± 4.0 vs. −3.3 ± 4.3; p=0.02) in patients with CKD progression. The patients in group 1 (n: 130) (Be<−2.5) revealed more CKD progression (%53 vs. %32; p=0.002), and RRT requirement (%35 vs. %15; p=0.001). Baseline BE <−2.5 (odds ratio, 0.38; 95% CI, 0.16 to 0.91; p<0.05) and baseline GFR (odds ratio, 0.94; 95% CI, 0.90 to 0.97; p<0.001) were independently related to RRT requirement. Delta BE was independently associated with mortality (odds ratio, 0.90; 95% CI, 0.85–0.96; p<0.01).
Conclusions
Low BE levels were associated with CKD progression and RRT requirement. BE change is associated with mortality during the follow-up of those patients.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry, medical,Clinical Biochemistry,Molecular Biology,Biochemistry
Reference31 articles.
1. Chen, W, Abramowitz, MK. Advances in management of chronic metabolic acidosis in chronic kidney disease. Curr Opin Nephrol Hypertens 2019;28:409–16. https://doi.org/10.1097/mnh.0000000000000524. 2. Di lorio, BR, Bellasi, A, Raphael, KL, Santoro, D, Aucella, F, Garofano, L, et al.. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol 2019;32:989–1001. https://doi.org/10.1007/s40620-019-00656-5. 3. Alva, S, Divyashree, M, Kamath, J, Prakash, PS, Prakash, KS. A study on effect of bicarbonate supplementation on the progression of chronic kidney disease. Indian J Nephrol 2020;30:91–7. https://doi.org/10.4103/ijn.IJN_93_19. 4. Kim, HJ, Kang, E, Ryu, H, Han, M, Lee, KB, Kim, YS, et al.. Metabolic acidosis is associated with pulse wave velocity in chronic kidney disease: results from the KNOW-CKD Study. Sci Rep 2019;9:16139. https://doi.org/10.1038/s41598-019-52499-6. 5. Abe, M, Akaishi, T, Shoji, M, Yamaguchi, T, Miki, T, Satoh, F, et al.. Reno-protective effects of oral alkalizing agents in chronic kidney disease aciduria: protocol for a randomized cohort study. BMC Nephrol 2020;21:144. https://doi.org/10.1186/s12882-020-01807-8.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|